started · updated
Alzheimer's blood test arrives in Brazil with over 90% precision
A new blood test for diagnosing Alzheimer's disease has arrived in Brazil, following registration by the National Health Surveillance Agency (Anvisa). The test, which identifies the p-tau217 protein, offers a less invasive alternative to traditional methods such as lumbar punctures or PET scans.
Researchers report the test achieves over 90% precision in detecting biomarkers associated with amyloid plaque accumulation. It is currently available at Hospital Moinhos de Vento in Porto Alegre, with a cost of approximately R$ 3,000. The procedure is intended for symptomatic patients aged 50 and older; it is not recommended for asymptomatic screening.
While the technology marks a significant advancement in neurological diagnostics, it is not yet available through the Unified Health System (SUS). The Ministry of Health has stated there is currently no formal request to incorporate the test into the public health network.
Entities
Anvisa · Fujirebio · Hospital Moinhos de Vento · Ministry of Health · Porto Alegre
Claims
What the coverage asserts, and how many sources carry each claim.
- [○ 1 SOURCE] The test is contraindicated for asymptomatic individuals and those under 50 years of age. www.ocafezinho.com
- [○ 1 SOURCE] Between 15% and 20% of samples yield intermediate results requiring further testing. www.ocafezinho.com
- [● 3 SOURCES] The test identifies the p-tau217 protein, a biomarker for Alzheimer's biological processes. www.ocafezinho.com
- [○ 1 SOURCE] The test is not currently available through the Unified Health System (SUS). www.ocafezinho.com
- [○ 1 SOURCE] Anvisa has registered the first blood test for Alzheimer's diagnosis available in Brazil. www.ocafezinho.com
- [● 3 SOURCES] The blood test can diagnose Alzheimer's with over 90% precision. www.ocafezinho.com
- [○ 1 SOURCE] The test is initially available at Hospital Moinhos de Vento in Porto Alegre and costs approximately R$ 3,000. www.ocafezinho.com